Published in PLoS One on August 27, 2013
Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes. Ther Adv Drug Saf (2014) 0.76
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Interaction revisited: the difference between two estimates. BMJ (2003) 11.97
Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med (2004) 9.10
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol (1997) 9.01
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA (2011) 5.93
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med (2009) 5.69
The hazards of hazard ratios. Epidemiology (2010) 5.24
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst (2007) 3.85
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost (2007) 3.38
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol (2009) 3.08
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ (2011) 2.68
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation (2009) 2.20
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J (2009) 1.92
Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ (2011) 1.86
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J (2009) 1.27
What is clinical utility and why should we care? Clin Pharmacol Ther (2010) 1.27
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost (2010) 1.25
A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther Clin Risk Manag (2007) 1.18
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health (2008) 1.16
The value of value of information: best informing research design and prioritization using current methods. Pharmacoeconomics (2010) 1.07
Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. Pharmacogenomics (2012) 0.96
Personalized medicine: potential, barriers and contemporary issues. Curr Drug Metab (2012) 0.82
Frequency of treatment-effect modification affecting indirect comparisons: a systematic review. Pharmacoeconomics (2010) 0.81
Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia. Pharmacoeconomics (2013) 0.81
Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment. Value Health (2011) 0.80
Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics. Clin Pharmacol Ther (2013) 0.80
Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. Lancet (2011) 5.13
Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat (2010) 4.58
Indirect comparison: relative risk fallacies and odds solution. J Clin Epidemiol (2009) 1.78
Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol (2012) 1.68
Anticipated behaviors of emergency prehospital medical care providers during an influenza pandemic. Prehosp Disaster Med (2010) 1.56
Cancer diagnosis, treatment, and survival in Indigenous and non-Indigenous Australians: a matched cohort study. Lancet (2006) 1.53
Contemporary management of renal cell carcinoma (RCC) in Victoria: implications for longer term outcomes and costs. BJU Int (2013) 1.50
Using routine inpatient data to identify patients at risk of hospital readmission. BMC Health Serv Res (2009) 1.47
Provision of taped conversations with neonatologists to mothers of babies in intensive care: randomised controlled trial. BMJ (2006) 1.45
Trends in melanoma mortality in Australia: 1950-2002 and their implications for melanoma control. Aust N Z J Public Health (2005) 1.10
A systematic review of two outcomes in autism spectrum disorder - epilepsy and mortality. Dev Med Child Neurol (2012) 1.09
Trends in birth size and macrosomia in Queensland, Australia, from 1988 to 2005. Paediatr Perinat Epidemiol (2009) 1.08
Cancer survival for Aboriginal and Torres Strait Islander Australians: a national study of survival rates and excess mortality. Popul Health Metr (2014) 1.07
TIDI addresses uncertainty but not indeterminism. Value Health (2013) 1.07
Identifying variations in quality of care in Queensland hospitals. Med J Aust (2007) 0.95
Patterns of surgical treatment for women diagnosed with early breast cancer in Queensland. Ann Surg Oncol (2007) 0.92
Detecting the start of an influenza outbreak using exponentially weighted moving average charts. BMC Med Inform Decis Mak (2010) 0.92
Reducing perinatal mortality among Indigenous babies in Queensland: should the first priority be better primary health care or better access to hospital care during confinement? Aust New Zealand Health Policy (2005) 0.85
Survival disparities in Australia: an analysis of patterns of care and comorbidities among indigenous and non-indigenous cancer patients. BMC Cancer (2014) 0.83
Impact of hospital-wide process redesign on clinical outcomes: a comparative study of internally versus externally led intervention. BMJ Qual Saf (2011) 0.81
The incidence of second primary invasive melanoma in Queensland, 1982-2003. Cancer Causes Control (2008) 0.79
Mortality from prostate cancer is decreasing. Med J Aust (2002) 0.79
A multilevel model of methicillin-resistant Staphylococcus aureus acquisition within the hierarchy of an Australian tertiary hospital. Am J Infect Control (2012) 0.78
Hospital morbidity data for determining spread of disease at diagnosis for colorectal cancer: a validation study. Asia Pac J Clin Oncol (2012) 0.78
Attitudes to living and working in pandemic conditions among emergency prehospital medical care personnel. Prehosp Disaster Med (2010) 0.77
Hospital-activity data inaccurate for determining spread-of-disease at diagnosis for non-small cell lung cancer. Aust N Z J Public Health (2012) 0.76
A hierarchical spatial modelling approach to investigate MRSA transmission in a tertiary hospital. BMC Infect Dis (2013) 0.75
Radiotherapy in the Barwon South Western Region: a rural perspective. J Med Imaging Radiat Oncol (2014) 0.75
Consistently estimating absolute risk difference when translating evidence to jurisdictions of interest. Pharmacoeconomics (2011) 0.75